Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Ascendis Pharma A/SNASDAQ: ASND

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income turns positive

Q3 FY2026 net income was €73.53M, compared with -€60.99M a year earlier. Trailing-twelve-month net income was €890.37M. Over 3 fiscal years it compounded at -27.9% a year.

Context

  • Net income amounted to 31.7% of revenue in FY2025, down 72.3 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 13 analysts of €919.16M (+519.6%) for the fiscal year ending Dec 2026, a step up from the -42.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
€73.53M-65.1% QoQ
Last fiscal yearDec 2025
-€219.03M-42.1% YoY
LTMSep 2026
€890.37M+482.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+220.6%+437.1%+216.6 pp
1 year-42.1%+519.6%+561.7 pp
3-year CAGR-27.9%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(219.03M) EUR
Year-over-year change
+42.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +482.2% is the 2nd highest of 11, against a peer median of +8.2%.
  • Net income amounts to 73.7% of revenue for ASND, versus a peer median of 41.6%.
ASND Competitors
Net Income for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$27.6B USD+3808.4%+35.1%2.7%
UTHRUnited Therapeutics CorporationLTM Jun 2026$1.31B USD+5.5%+22.4%41.6%
ASNDAscendis Pharma A/SLTM Sep 2026€890.37M EUR+482.2%-27.9%73.7%
INSMInsmed IncorporatedLTM Jun 2026$875.31M USD-15.4%+38.4%76.9%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$702.5M USD+64.1%+45.8%19.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$608.92M USD+10.8%-6.7%91.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$169.77M USD-437.7%-59.2%529.2%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$145.1M USD+80.3%+49.3%—
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$128.76M USD-3.0%-1.1%15.5%
SEPNSepterna, Inc.LTM Sep 2026$59M USD+0.3%+20.9%61.3%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.01M USD+126.6%—3.8%
Peer median (excluding ASND) —+8.2%+22.4%41.6%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
Deferred Income Tax(367K)5.38M7.3M4.84M3.21M
Stock-Based Compensation66.83M64.18M66.66M95.51M0
Change in Working Capital(47.72M)(12.47M)(99.79M)(107.16M)68.16M
Accounts Receivables(6.66M)(11.53M)(32.77M)(118.61M)14.97M
Inventory(75.41M)(55.27M)(78.26M)(86.68M)(5.69M)
Accounts Payables0000(9.96M)
Other Working Capital34.34M54.33M11.25M98.13M68.84M
Other Non-Cash Items(68.21M)12.45M21M60.98M182.44M
Operating Cash Flow(417.65M)(495.7M)(467.36M)(306.2M)51.77M
Capital Expenditures(24.23M)(14.49M)(2.44M)(1.43M)(8.15M)
Acquisitions (Net)(10.19M)0000
Purchases of Investments(226.04M)(213.84M)000
Sales of Investments149.88M280.53M07.35M0
Other Investing Activities(530K)9.54M288.92M950K0
Investing Cash Flow(110.58M)61.73M286.47M6.88M(8.15M)
Debt Repayment(6.43M)496.93M125.82M122.79M(21.09M)
Common Stock Issued367.88M00309.91M83.64M
Common Stock Repurchased(21.61M)(105.31M)(1.81M)0(16.71M)
Dividends Paid00000
Other Financing Activities11.54M5.15M10.29M11.22M(10.95M)
Financing Cash Flow351.39M396.77M134.29M443.93M34.89M
Effect of Forex Changes38.59M35.69M(6.01M)22.77M44.13M
Net Change in Cash(138.25M)(1.5M)(52.6M)167.38M122.65M
Free Cash Flow(441.88M)(510.19M)(469.8M)(307.62M)43.62M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.